Novo Nordisk plans to make bariatric surgery a thing of the past: The key is not one but two drugs

Combinations of at least two different drugs have become an important element of Novo Nordisk's future plans within obesity, fatty liver disease and diabetes. One combination in particular looks set to become a top product, says chief science officer.

Mads Krogsgaard Thomsen, CSO at Novo Nordisk, eyes a potential in drug combinations. Photo: Jacob Ehrbahn/Politiken

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles